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Antidepressant treatment and cultural differences
- a survey of the attitudes of physicians and
patients in Sweden and Turkey
Alan G Wade1*, Paul CD Johnson2, Alex McConnachie2
Abstract
Background: The presenting symptoms of depression can be influenced by cultural differences. This study was
conducted to compare the presenting symptoms and response to antidepressant medication of patients in
Sweden and Turkey, two culturally different European countries.
Methods: Recruitment was triggered when adult patients were diagnosed with a depressive or anxiety disorder by
a primary care physician and prescribed an antidepressant. Physicians and patients recorded presenting symptoms
and completed relevant questionnaires just before and 8 weeks after starting treatment with an antidepressant.
These included the Hospital Anxiety and Depression Scale (HADS), the Clinical Global Impressions (CGI) scale, the
Sheehan Disability Scale (SDS), and Likert scales gauging the importance of physical and psychological symptoms.
Patients also rated severity of prominent symptoms (depression, anxiety, stress, sleep and pain) from zero to ten.
The outcomes were compared between patients from Sweden and Turkey using Fisher’s Exact test and two-
sample t-tests.
Results: The study was conducted in 460 patients (107, 23.3% in Sweden; 353, 76.7% in Turkey). Presenting
symptoms differed between Sweden and Turkey, with Turkish patients more likely to present with physical
symptoms, and report a higher number of physical symptoms (mean 2.4 vs. 1.4, p < 0.001). In both countries, the
diagnosis made by the physician differed from that derived from the HADS score at the start of the study. The
HADS diagnosis varied between the countries with significantly different proportions of patients in each country
being diagnosed with depression alone, anxiety alone or depression with anxiety. While all symptoms improved
after antidepressant treatment in both countries, Turkish patients showed a greater degree of response than
Swedish patients in depression (p = 0.048), stress (p = 0.014) and pain (p < 0.001) as measured by the prominent
symptoms assessment (PSA).
Conclusions: The presenting symptoms of patients diagnosed with a depressive or anxiety disorder by a primary
care physician and prescribed an antidepressant differ between Turkey and Sweden. Patients in Turkey were more
likely to present with physical symptoms than patients in Sweden and present with more physical symptoms. After
8 weeks of antidepressant treatment, the improvement from baseline was greater in Turkish patients, and this was
reflected in their improved functioning.
Background
Depression is a common and disabling mental illness,
which ‘refers to a wide range of mental health problems
characterised by the absence of a positive effect, low
mood and a range of associated emotional, cognitive,
physical and behavioural symptoms’ [1]. Patients may
present in many ways with physical, social or psycholo-
gical symptoms to primary care physicians [2], and phy-
sical symptoms such as fatigue, headache, abdominal
distress, or change in weight are often the presenting
complaints in the primary care setting [3]. The diagnosis
and classification of depression using DSM-IV and ICD-
10 are based mainly on psychological symptoms [3,4],
which may make it harder for primary care physicians
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to correctly diagnose depression in patients presenting
with physical symptoms.
The symptomatic presentation of depression is known
to vary between cultural groups [5,6]. People from non-
Western cultures are more likely to use phrases that
allude to physical sensations [6]. The World Organisa-
tion of Family Doctors (WONCA) culturally sensitive
depression guideline notes that ‘The primary care physi-
cian needs to understand the cultural, religious and
gender paradigm that the individual brings to the con-
sultation in order to increase the chance of establishing
a therapeutic alliance that reduces the personal distance
between physician and patient. This will maximise the
chance of therapeutic success’ [6].
Little is known about why a primary care physician
prescribes an antidepressant in response to a diagnosis
based on anxiety symptoms or depressive symptoms.
Undoubtedly the decision is influenced by the interaction
between physician and patient, the manner in which the
patient presents and by differing cultural factors.
There are demographic and cultural differences
between Sweden and Turkey. Sweden is a Western Eur-
opean country with a population with a median age of
41.5 years [7]. The majority of the population are Swed-
ish born (87%) [8], live in urban areas (85%) and are
Lutheran (87%) [7]. Turkey is an Eastern European
country, which has a younger population with a median
age of 27.7 years; with 31% living in rural areas [7]. The
Turkish population are 70-75% Turkish ethnicity with
18% of Kurdish ethnicity and the population is almost
entirely Muslim (99.8%).
The aim of the current study was to compare the fol-
lowing outcomes for patients prescribed antidepressants
for 8 weeks in primary care in Sweden and Turkey:
1. Presenting symptoms of depression reported by
the patient and their perceived relative importance
to the patient, and patient-reported outcomes from
the Hospital Anxiety and Depression Scale (HADS),
Sheehan Disability Scale and a prominent symptoms
assessment scale
2. Presenting symptoms of depression noted by the
patient’s physician and their perceived relative
importance
3. Presumptive diagnosis by the physician compared
with a diagnosis determined by the HADS scale
4. Changes in symptoms after 8 weeks of antidepres-
sant treatment as assessed by patient-reported out-
comes and the patient’s physician
Methods
Study design
This was an 8-week naturalistic study designed to compare
presenting symptoms and response to antidepressant
medication in adult patients prescribed an antidepressant
by their primary care physician in Sweden and Turkey,
two culturally different European countries. The study was
approved by the appropriate ethical committees in Sweden
(Uppsala Regional Ethics Committee) and Turkey (Eftal
Training and Research Hospital, Istanbul) in accordance
with the International Conference on Harmonization
(ICH) guidelines for Good Clinical Practice (GCP).
Patients
Recruitment to the study was triggered by primary care
physicians first prescribing an antidepressant to patients
aged 18-80. There were no specific exclusion criteria.
Concomitant medications, including anxiolytics and
analgesics, were allowed. A total of 460 consecutive con-
senting patients, 107 of whom (23.3%) were recruited in
Sweden and 353 (76.7%) in Turkey, were enrolled in the
study by 65 primary care physicians (43 in Turkey and
22 in Sweden) between October 2004 and August 2006.
Ethics
The study was approved by the appropriate ethical com-
mittees in Sweden and Turkey in accordance with the
International Conference on Harmonization (ICH)
guidelines for Good Clinical Practice (GCP) [9].
Outcome measures
Following informed patient consent, parallel question-
naires were independently completed by the physician
and patient. The diagnosis triggering the decision to
prescribe an antidepressant was recorded by the physi-
cian, and for comparison, the patient completed the
self-rating Hospital Anxiety and Depression Scale
(HADS) [10]. Depression without anxiety was defined as
a HADS-Depression score ≥11 and a HADS-Anxiety
score <11; depression with anxiety was defined as a
score ≥11 for both the HADS-Depression and HADS-
Anxiety subscales; and anxiety without depression was
defined as a HADS-Anxiety score ≥11 and a HADS-
Depression score <11. Patients scoring <11 on both
scales were ‘unassigned’. The degree of illness was
assessed by the physician using the Clinical Global
Impression Severity (CGI-S) scale [11] and by patients
completing a battery of five scales of prominent symp-
toms (depression, anxiety, stress, sleep and pain, rated
from zero to ten). In a separate analysis we have shown
that the prominent symptoms assessment scale reliably
reflects prominent symptoms of depression (unpublished
data). The physical and psychological symptoms
reported by the patient on presentation were also
recorded by the physician. The importance of a range of
psychological (depression, anxiety, stress and sleep pro-
blems) and physical (fatigue, gastro-intestinal [GI] dis-
turbance, headache, pain and backache) symptoms was
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assessed by both the physician and the patient on a scale
from 1-5. The Sheehan Disability Scale (SDS) was used
as a self-rated scale to assess the degree of disability in
relation to work, social life and family life, based on the
previous week [12]. Each of these 3 domains was rated
from 0 to 10 (no impairment to most severe impair-
ment). The same questionnaires were also completed
after 8 weeks to provide information about patient out-
come and relative changes in patient symptoms. In addi-
tion, patients self-rated their overall improvement using
the CGI improvement scale (CGI-I) at 8 weeks, and
physicians assessed compliance with antidepressant
medication (defined as the patient reporting that they
were still taking antidepressant medication at Week 8).
Statistical methods
Differences between countries were explored initially
using Fisher’s Exact test and two-sample t-tests. Signifi-
cant associations were investigated further using linear
mixed effects regression models fitted using restricted
maximum likelihood, adjusting for the effects of age and
sex, and for heterogeneity between physician practices.
Results
Patient population
The demographic characteristics of the study population
at baseline are summarised in Table 1. The proportion
of women recruited in Turkey was higher than in Swe-
den, although most patients in both countries were
women. While the majority of patients in both countries
were aged between 35-49 years, the mean age of
patients recruited in Turkey was 11 years lower than in
Sweden.
Presenting symptoms
A higher proportion of Turkish patients (75.6%) than
Swedish patients (65.4%) presented with symptoms of
depression (p = 0.046). There were no other significant
differences between countries with respect to the cate-
gory or number of presenting psychological symptoms
at baseline (Table 1).
Turkish patients were more likely to present with phy-
sical symptoms of fatigue, pain, GI disturbance, cardio-
vascular and CNS problems than Swedish patients
(Table 1). The mean number of physical symptoms
reported by patients in Turkey was also greater than in
Sweden (2.4 vs. 1.4, p < 0.001; Figure 1b, Table 1).
The duration of the presenting symptoms prior to a
patient first visiting the physician did not differ signifi-
cantly between countries; the majority of patients
(84.1%) had experienced symptoms for more than one
month.
Patients in Turkey scored significantly higher than
their Swedish counterparts on the depression, stress and
pain components of the patient-reported prominent
symptoms (Figure 1d-f, Table 1), with no evidence of
association between the prominent symptoms depres-
sion scores and age or sex.
The proportion of patients with severe or extreme ill-
ness as assessed by the physician using the CGI-S was
significantly greater in Turkey (36.6%) than in Sweden
(4.8%), (p < 0.001), as was the mean CGI-S score (Figure
1g, Table 1).
Importance of symptoms
The importance of physical symptoms was rated higher
in Turkey than in Sweden (mean values of 2.98 vs.
2.42, p < 0.001) by the physician, while the patient’s
rating did not differ between countries. A contrasting
pattern was observed for psychological symptoms.
There was no difference between countries in the phy-
sician’s mean assessment of importance, but patients
rated the importance of psychological symptoms
higher in Sweden than in Turkey (mean values of 3.87
vs. 3.49, p < 0.001). The general pattern of physicians
rating the importance of physical symptoms higher in
Turkey and patients rating psychological symptoms as
more important in Sweden reflects the between-coun-
try differences apparent in the individual symptoms
(Figure 2). An exception to this pattern was fatigue,
which follows the pattern of psychological symptoms,
and was rated as more important by patients in Swe-
den than in Turkey.
Diagnosis (Physician and HADS)
There was no significant difference between the coun-
tries in the physician’s initial diagnosis. However, in
both countries the physician’s diagnosis differed from
the diagnosis obtained by the HADS, with anxiety being
under-diagnosed by physicians (Table 2). A statistically
significant difference between the countries in diagnosis
as measured by the HADS at the first visit was observed
(p < 0.001). Figure 1c shows that patients in Turkey
scored significantly higher on the HADS-Depression
scale than patients in Sweden (see also Table 1). No
associations were found between HADS-Depression
scores and age or sex.
Medication
Selective serotonin reuptake inhibitors (SSRIs) were the
most commonly prescribed class of antidepressant at
the first visit, with the majority of patients in both Swe-
den (88.0%) and Turkey (93.2%) being prescribed at
least one SSRI (Table 1). Antidepressants other than
SSRIs, venlafaxine or mirtazapine were not prescribed in
Sweden, whereas tricyclic antidepressants (TCAs) and
other antidepressants were prescribed for a small minor-
ity of Turkish patients.
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Changes in symptoms after 8 weeks
The proportion of patients returning for their 8-week
visit was higher in Turkey than in Sweden (92.9% vs.
76.6%, p < 0.001). We investigated the potential for the
higher dropout rate in Sweden to bias the results by
comparing the baseline characteristics listed in Table 1
between returners and non-returners within each coun-
try (data non shown). In Sweden, none of the outcomes
differed significantly, while in Turkey non-returners had
lower CGI severity, were less likely to have presented
with pain and had fewer physical presenting symptoms.
Substantial bias is therefore unlikely because of the low
dropout rate in Turkey and the similarity between retur-
ners and non-returners in Sweden.
The results of the overall improvement in the patient’s
condition using the CGI-I scale, as assessed by the physi-
cian and the patient are shown in Table 3. The distribu-
tions of the assessments (very much improved, much
improved, minimal improvement or same/worse), were
similar between physicians and patients, and in agreement
70.3% of the time; physician-patient agreement was higher
in Turkey than in Sweden (73% vs. 61%, p = 0.040).
Comparison of the patients’ mean rating of the impor-
tance of symptoms at the first and second visits showed
Table 1 Demographic and mental health characteristics of the study population on prescription of an antidepressant
(baseline), by country
Characteristic Sweden (n = 107) Turkey (n = 353) P-value
Sex, n (%) Female 58 (55.2%) 269 (76.4%) <0.001
Age Mean ± SD (n) 51.1 ± 14.7 (100) 39.9 ± 11.5 (340) <0.001
CGI-Severity a Mean ± SD (n) 4.4 ± 0.8 (105) 5.1 ± 1.1 (344) <0.001
Medications prescribed, n (%) SSRIs 66 (88.0%) 275 (93.2%) 0.149
TCAs 0 (0.0%) 5 (1.7%) 0.588
Venlafaxine 3 (4.0%) 6 (2.0%) 0.395
Mirtazapine 7 (9.3%) 8 (2.7%) 0.017
Other ADs 0 (0.0%) 20 (6.8%) 0.018
Anxiolytics 5 (6.7%) 52 (17.6%) 0.019
Hypnotics 11 (14.7%) 2 (0.7%) <0.001
Analgesics 10 (13.3%) 15 (5.1%) 0.018
Presenting symptoms (psychological), n (%) a Depression 70 (65.4%) 267 (75.6%) 0.046
Anxiety 55 (51.4%) 188 (53.3%) 0.742
Sleep 55 (51.4%) 201 (56.9%) 0.320
Presenting symptoms (physical), n (%) a Fatigue 47 (43.9%) 200 (56.7%) 0.027
Pain 40 (37.4%) 209 (59.2%) <0.001
Gastro-intestinal 21 (19.6%) 150 (42.5%) <0.001
Cardiovascular 8 (7.5%) 86 (24.4%) <0.001
CNS 29 (27.1%) 194 (55.0%) <0.001
Number of psychological symptoms a Mean ± SD (n) 1.7 ± 0.9 (107) 1.9 ± 0.9 (353) 0.067
Number of physical symptoms a Mean ± SD (n) 1.4 ± 1.1 (107) 2.4 ± 1.3 (353) <0.001
HADS-Depression b Mean ± SD (n) 10.3 ± 4.2 (99) 12.8 ± 4.5 (335) <0.001
HADS-Anxiety b Mean ± SD (n) 12.9 ± 4.0 (99) 12.6 ± 4.0 (335) 0.577
Prominent symptoms-Depression b Mean ± SD (n) 5.9 ± 2.2 (97) 6.8 ± 2.6 (342) 0.005
Prominent symptoms-Anxiety b Mean ± SD (n) 5.7 ± 2.4 (101) 6.1 ± 2.8 (339) 0.259
Prominent symptoms-Stress b Mean ± SD (n) 6.2 ± 2.6 (101) 6.9 ± 2.5 (341) 0.010
Prominent symptoms-Sleep b Mean ± SD (n) 5.9 ± 2.9 (101) 6.4 ± 2.9 (341) 0.158
Prominent symptoms-Pain b Mean ± SD (n) 4.8 ± 3.1 (101) 6.2 ± 2.8 (342) <0.001
SDS-Work b Mean ± SD (n) 6.0 ± 3.2 (98) 6.0 ± 2.7 (332) 0.873
SDS-Social b Mean ± SD (n) 6.9 ± 2.5 (102) 6.8 ± 2.5 (342) 0.564
SDS-Family b Mean ± SD (n) 6.6 ± 2.5 (102) 6.5 ± 2.6 (342) 0.882
a As assessed/recorded by the primary care physician
b As assessed/recorded by the patient
Abbreviations: AD: antidepressant, CGI-S: Clinical Global Impression Severity Scale, HADS: Hospital Anxiety and Depression Scale, SD: standard deviation, SDS:
Sheehan Disability Scale, SSRI: selective serotonin reuptake inhibitor, TCA: tricyclic antidepressant
P-values from two sample t-test
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Figure 1 Mean (95% CI) outcome variables at presentation, by country, and by sex and age category within each country. The number
of psychological and physical symptoms reported at presentation; the HADS depression score and prominent symptoms scores for depression,
stress and pain score assessed by the patient; and the CGI-severity (CGI-S) score assessed by the physician are shown. P-values are from tests of
association between outcome and the covariates country, sex and age from three univariate linear mixed effects regression models (unadj), and
from a multivariate model where the effect of each covariate is adjusted for the effects of the other two (adj).
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Figure 2 Mean (95% CI) importance of symptoms in Swedish and Turkish patients, assessed by the physician (GP) and the patient
(Pat). Asterisks indicate a significant difference between countries (mixed effects linear regression model adjusted for age and sex: *p < 0.05;
**p < 0.01; ***p < 0.001). Importance was rated on a 5 point scale (1, not present; 2, present but not important; 3, present; 4, important but not
major complaint; 5, very important). GI: gastro-intestinal symptoms.
Wade et al. BMC Family Practice 2010, 11:93
http://www.biomedcentral.com/1471-2296/11/93
Page 6 of 9
a reduction in all symptoms from baseline (data not
shown). The changes in mean HADS, prominent symp-
toms and SDS scores from baseline to Week 8 are com-
pared by country in Figure 3. The degree of
improvement was greater in Turkish patients than in
Swedish patients across all measures, although this was
significant only for three prominent symptoms (PSA-
depression: p = 0.048; PSA-stress: p = 0.014; PSA-pain:
p < 0.001). Having had higher HADS-Depression scores
at the first visit, Turkish patients improved to near par-
ity with Swedish patients at Week 8 (Figure 3). How-
ever, the degree of improvement did not differ
significantly between Turkey and Sweden (mean 6.57 vs.
4.97, p = 0.076). There were no significant differences
between the countries in mean SDS scores at baseline,
but at Week 8 patients in Turkey had lower mean
scores on the Work (p = 0.009) and Social (p = 0.039).
Medication at Week 8
Over 90% of patients returning for the second visit at
Week 8 received a further prescription of antidepressant
medication. Table 4 compares the use of concomitant
medication at baseline and Week 8. Approximately half
the patients initially prescribed anxiolytics received a
further prescription (3.6% in Sweden and 7.9% in
Turkey). In addition, 10.7% of Swedish patients received
a further prescription for hypnotics and 12.5% for addi-
tional analgesics. Repeat prescription of hypnotics and
analgesics was minimal in Turkey.
Treatment compliance (patient’s reported adherence
to the prescribed course of antidepressant treatment
assessed at the second visit at Week 8) was high overall
but did not differ significantly between Turkey and Swe-
den (93.7% vs. 90.2%, p < 0.329).
Discussion
This study showed no significant difference between pri-
mary care physicians in Turkey and Sweden in assigning
a diagnosis of depression, anxiety or mixed depression/
anxiety to patients prescribed an antidepressant. The
patient, however, reported that presenting symptoms,
HADS diagnosis and treatment response differed
between the two countries. Patients recruited in Turkey
were significantly more likely than Swedish patients to
present with physical symptoms. They also reported a
higher number of physical symptoms and perceived them
to be more important than their Swedish counterparts.
The differences noted between the study participants
recruited in Sweden and Turkey may reflect the relative
demography of the two countries’ populations, although
Table 2 Number (%) of patients with main diagnosis according to the primary care physician and the HADS
categories, and agreement between the physician and HADS
Diagnostic method Sweden (n = 107) Turkey (n = 353) P-value
Physician diagnosis, n (%) Depression alone 53 (52.0%) 155 (45.2%)
Depression + anxiety 46 (45.1%) 158 (46.1%) 0.104
Anxiety alone 3 (2.9%) 30 (8.7%)
HADS diagnosis, n (%) Depression alone 4 (4.0%) 56 (16.7%)
Depression + anxiety 43 (43.4%) 176 (52.5%) <0.001
Anxiety alone 33 (33.3%) 65 (19.4%)
Non-assigned 19 (19.2%) 38 (11.3%)
Physician-HADS agreement, n (%) Same diagnosis 33 (35.1%) 162 (49.8%) 0.014
Abbreviations: HADS: Hospital Anxiety and Depression Scale
P-values from tests of equal prevalence (Fisher Exact test)
Table 3 Number (%) of patients with CGI-I rating after 8 weeks of antidepressant treatment according to the primary
care physician and the patient, and agreement between physician and patient
Measure Sweden (2) Turkey (n = 328) P-value
Physician CGI-I, n (%) Very much improved 10 (12.2%) 73 (23.1%)
Much improved 40 (48.8%) 184 (58.2%) 0.001
Minimal improved 23 (28.0%) 46 (14.6%)
Same/worse 9 (11.0%) 13 (4.1%)
Patient CGI-I, n (%) Very much improved 7 (8.9%) 85 (27.2%)
Much improved 31 (39.2%) 173 (55.3%) <0.001
Minimal improved 31 (39.2%) 27 (8.6%)
Same/worse 10 (12.7%) 28 (8.9%)
Physician-patient agreement, n (%) Same assessment 48 (60.8%) 227 (72.8%) 0.040
P-values from tests of equal prevalence (Fisher Exact test)
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cultural differences in the other factors leading to pre-
scription of an antidepressant - such as the incidence of
depression, tendency to visit a physician and accuracy of
diagnosis - could also have contributed to this pattern.
Based on the self-reported HADS scores, using the high
score of 11 as indicating caseness [13], significantly dif-
ferent proportions of patients in each country were pre-
scribed antidepressants for depression alone, anxiety
alone or depression with anxiety. Physicians in both
countries were more likely to make a diagnosis of depres-
sion whilst acknowledging the presence of anxiety symp-
toms and apparently recognising their importance. This
tendency may reflect the increasing recommendation for
and use of antidepressants for symptoms of anxiety.
Turkish patients also tended to show a greater degree
of response after 8 weeks of antidepressant treatment
than Swedish patients and one might speculate that this
could be associated with the higher proportion of
patients in the Swedish cohort self-reporting anxiety
symptoms which may be less responsive to antidepres-
sant treatment. Whatever the reason, the symptomatic
improvement observed in Turkish patients is reflected
in significantly better functioning at Week 8 within the
work and social domains of the SDS in comparison to
the Swedish population (Figure 3).
Somatisation was more frequent among Turkish
patients than among Swedish patients and this is a com-
mon explanation for the apparent under-recognition of
depressive disorders in non-Western cultures [6].
Patients and physicians in Turkey - but not in Sweden -
often agreed upon the importance assigned to pain, sug-
gesting that Turkish physicians are cognizant of the
patient’s cultural background and associated tendency to
allude to physical rather than psychological symptoms.
Analysis of the HADS and prominent symptoms
results reveals that symptoms of depression were more
severe at baseline in Turkey compared with Sweden.
Furthermore, the extent improvement in depression
symptoms after prescription of an antidepressant for 8
weeks was significantly greater in Turkish patients than
in Swedish patients. This suggests that Turkish patients
responded better to treatment, or at least were more
satisfied with the treatment, or gave more extreme rat-
ings of symptoms when depressed or anxious. It is pos-
sible that these results do not indicate that Turkish
patients are more depressed at baseline but that the
HADS does not translate well in this culture. However,
this is not supported by the prominent symptoms result,
which showed a marginally non-significant difference, or
by the CGI-S. The more likely explanation is that Turk-
ish patients are more depressed because they go to their
physician less readily or because Turkish primary care
physicians have a higher prescribing threshold. Never-
theless Ozmen et al. concluded that the general public
in Turkey believe that depression is a treatable illness
[14]. It is, therefore, possible that these results may in
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Figure 3 Mean (±95% CI) HADS, prominent symptoms and SDS scores in Swedish and Turkish patients. Asterisks above points indicate a
significant difference between countries in mean score at Visit 1 (baseline) and Visit 2 (Week 8), and in mean change between visits. Asterisks
between points indicate significant differences in the degree of change of symptoms between countries. (mixed effects linear regression model
adjusted for age and sex: *p < 0.05; **p < 0.01; ***p < 0.001).
Table 4 Number (%) of patients with concomitant medication of anxiolytics, hypnotics and analgesics on prescription
of an antidepressant (baseline) and after 8 weeks of antidepressant treatment
Concomitant medication Baseline Week 8
Sweden n (%) Turkey n (%) p-value Sweden n (%) Turkey n (%) p-value
Anxiolytics 5 (6.7%) 52 (17.6%) 0.019 2 (3.6%) 22 (7.9%) 0.394
Hypnotics 11 (14.7%) 2 (0.7%) <0.001 6 (10.7%) 0 (0.0%) <0.001
Analgesics 10 (13.3%) 15 (5.1%) 0.018 7 (12.5%) 5 (1.8%) 0.001
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part be due to this cultural belief, although Ozmen sug-
gests that the public has an optimistic view about the
prognosis and treatment of depression, whatever their
cultural characteristics.
A further possibility is that differences in the choice of
prescribed medication influence these results. The major-
ity of physicians in both countries prescribed SSRIs, but
some significant differences were noted between the
countries in other drugs prescribed. For example, anxio-
lytics were more commonly co-prescribed in Turkey,
while hypnotics and analgesics were more common in
Sweden, although there was no difference between coun-
tries in the prevalence of anxiety or sleep as presenting
complaints, nor in their severity as measured by the
HADS and prominent symptoms scale. Pain was a more
common presenting complaint in Turkey compared with
Sweden, which seems to contradict the lower level of
analgesics prescribed, unless these drugs were already
prescribed or purchased over the counter and having the
desired effect in Swedish patients.
The difference in presenting symptoms observed in this
study most likely reflect cultural differences between Swe-
den and Turkey. In countries populated by diverse ethnic
groups, it is important that physicians are aware of cultural
differences in patients’ presentation and expectations. The
disparity observed between the diagnosis recorded by phy-
sicians and that derived from the HADS scale may have
implications for both clinical practice and multicenter
clinical studies in depression and anxiety conducted across
countries with differing cultural backgrounds or across dif-
fering ethnic groups within a country.
Limitations
The practices chosen were self selected and cannot be
guaranteed to be representative of the totality of the pri-
mary care provision in either country.
This was a naturalistic study where the diagnosis of
anxiety or depression was not substantiated by formal
rating scales.
The report of adherence to medication is based solely
on the patient report which has been shown to be
potentially unreliable.
Conclusions
This study shows that the presenting symptoms of
patients diagnosed with a depressive or anxiety disorder
by a primary care physician and prescribed an antide-
pressant differ between Turkey and Sweden. Patients in
Turkey were more likely to present with physical symp-
toms than patients in Sweden and presented with more
physical symptoms. After 8 weeks of antidepressant
treatment, the improvement from baseline was greater
in Turkish patients, and this was reflected in their
improved functioning.
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